Policies regarding use of medications for opioid use disorder in professional recovery programs: A scoping review.

Subst Abus. 2022. DOI: 10.1080/08897077.2021.2010161

White KM, Hill LG, Perez JC, Torrez SB, Zagorski CM, Loera LJ.

Availability of buprenorphine/naloxone films and naloxone nasal spray in community pharmacies in Texas, USA

Addiction. 2021. DOI: 10.1111/add.15314

Hill LG, Loera LJ, Evoy KE, Torrez SB, Renfro ML, Zagorski CM, Perez JC, Jones SM, Reveles KR. 

Considering the potential benefits of over-the-counter naloxone

Integr Pharm Res Pract. 2021. DOI: 10.2147/iprp.S244709

Evoy KE, Hill LG, Davis CS. 

Leveraging pharmacists to maintain and extend buprenorphine supply for opioid use disorder amid COVID-19

Am J Health Syst Pharm. 2021. DOI: 10.1093/ajhp/zxab003

Peckham AM, Ball J, Colvard MD, Dadiomov D, Hill LG, Nichols SD, Tallian K, Ventricelli DJ, Tran TH. 

Operation Naloxone: Overdose prevention service learning for student pharmacists

Curr Pharm Teach Learn.  2018. DOI: 10.1016/j.cptl.2018.07.010

Hill LG, Sanchez JP, Laguado SA, Lawson KA.

Development of a health communication campaign to promote the Texas prescription monitoring program

Health Mark Q. 2020. DOI: 10.1080/07359683.2020.1802967

Mackert M, Pounders K, Brown L, Kirtz S, Hughes Wagner J, Ring D, Hill LG, Wilcox G, Murthy D, Tierney W, Innerarity S, McGlone M, Holleran Steiker LK, DeSalvo K, Bernhardt J, Pretorius K. 

Impact of student pharmacist-led naloxone academic detailing at community pharmacies in Texas

J Am Pharm Assoc. 2020. DOI: 10.1016/j.japh.2019.09.007

Evoy KE, Groff L, Hill LG, Godinez W, Gandhi R, Reveles KR. 

Implementation of a collaborative model for opioid overdose prevention on campus

J Am Coll Health. 2020. DOI: 10.1080/07448481.2018.1549049

Hill LG, Holleran Steiker LK, Mazin L, Kinzly ML.

Increasing naloxone knowledge and use through direct-to-patient education

J Pharm Technol. 2020. DOI: 10.1177/8755122520954218

Litten K, Hill LG, Garza A, Srinivasa M.

Isotonitazene as a contaminant of concern in the illegal opioid supply: A practical synthesis and cost perspective

Int J Drug Policy. 2020. DOI: 10.1016/j.drugpo.2020.102939

Zagorski CM, Myslinski JM, Hill LG. 

Lofexidine for acute opioid withdrawal: A clinical case series

Ment Health Clin. 2020. DOI: 10.9740/mhc.2020.09.259

Renfro ML, Loera LJ, Tirado CF, Hill LG. 

Mobilizing pharmacists to address the opioid crisis, a joint opinion of the ambulatory care and adult medicine practice and research networks for the American College of Clinical Pharmacy

J Am Coll Clin Pharm. 2020. DOI: 10.1002/jac5.1331

Coon SA, Hill LG, Hutchison RW, Arnold LM, Jarrett JB, Ottney AR, Oung AB, Painter NA, Smith MA, Stranges PM, Tran TH, McFee Winans AR, Bratberg JP. 

Reply to a letter regarding, “Pharmacists are missing an opportunity to save lives and advance the profession by embracing opioid harm reduction”

J Am Pharm Assoc. 2020. DOI: 10.1016/j.japh.2020.02.019

Hill LG, Evoy KE, Reveles KR. 

Report of the 2020 special committee on substance use and pharmacy education

Am J Pharm Educ. 2020. DOI: 10.5688/ajpe8421

Tran T, Ball J, Bratberg JP, DeSimone EM, Franko TS, Hill LG, Koh-Knox Sharp CP, Palombi L, Ventricelli D, Farrell D, Gandhi N, Moore T. 

Type and extent of opioid-related education provided by U.S. college of pharmacy continuing education divisions

Am J Pharm Educ. 2020. DOI: 10.5688/ajpe8001

Renfro ML, Moczygemba LR, Baumgartner J, Baumgart G, Hill LG.

Guidance for male mentors to support the safety and success of female mentees

Am J Pharm Educ. 2019. DOI: 10.5688/ajpe7533

Hill LG, Laguado SA.

Pharmacists are missing an opportunity to save lives and advance the profession by embracing opioid harm reduction

J Am Pharm Assoc. 2019. DOI: 10.1016/j.japh.2019.06.019

Hill LG, Evoy KE, Reveles KR. 

State-level approaches to expanding pharmacists’ authority to dispense naloxone may affect accessibility

JAMA Intern Med. 2019. DOI: 10.1001/jamainternmed.2019.3653

Hill LG, Reveles KR, Evoy KE. 

Naloxone accessibility without a prescriber encounter under standing orders at community pharmacy chains in Texas

JAMA. 2018. DOI: 10.1001/jama.2018.15892

Evoy KE, Hill LG, Groff L, Mazin L, Carlson CC, Reveles KR. 

Naloxone counseling for harm reduction and patient engagement

Fam Med. 2017. PMID: 29045991

Han JK, Hill LG, Koenig ME, Das N.